Pleural effusion in lung cancer: more questions than answers
ME Froudarakis - Respiration, 2012 - karger.com
Lung cancer remains the most common fatal malignancy, despite more aggressive
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
Pleural effusion in lung cancer: more questions than answers.
ME Froudarakis - Respiration; International Review of Thoracic …, 2012 - europepmc.org
Lung cancer remains the most common fatal malignancy, despite more aggressive
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
Pleural effusion in lung cancer: more questions than answers
ME Froudarakis - Respiration; international review of …, 2012 - pubmed.ncbi.nlm.nih.gov
Lung cancer remains the most common fatal malignancy, despite more aggressive
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
[PDF][PDF] Pleural Effusion in Lung Cancer: More Questions than Answers
ME Froudarakis - Respiration, 2012 - scholar.archive.org
Lung cancer remains the most common fatal malignancy, despite more aggressive
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
Pleural Effusion in Lung Cancer: More Questions than Answers
ME Froudarakis - Respiration, 2012 - karger.com
Lung cancer remains the most common fatal malignancy, despite more aggressive
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
Pleural Effusion in Lung Cancer: More Questions than Answers
ME Froudarakis - Respiration, 2012 - search.proquest.com
Lung cancer remains the most common fatal malignancy, despite more aggressive
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
[PDF][PDF] Pleural Effusion in Lung Cancer: More Questions than Answers
ME Froudarakis - Respiration, 2012 - academia.edu
Lung cancer remains the most common fatal malignancy, despite more aggressive
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
Pleural Effusion in Lung Cancer: More Questions than Answers.
ME Froudarakis - Respiration, 2012 - search.ebscohost.com
Lung cancer remains the most common fatal malignancy, despite more aggressive
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
[PDF][PDF] Pleural Effusion in Lung Cancer: More Questions than Answers
ME Froudarakis - Respiration, 2012 - academia.edu
Lung cancer remains the most common fatal malignancy, despite more aggressive
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …